Organ Transplant · Chapter 1
The Transplant Decision Framework
How to think about psychotropic prescribing when a transplanted organ is the constraint — why the immunosuppressant interaction, not the dose, is the axis that matters; why the downside here isn’t a side effect but the graft itself; and the direction the other courses never had to track: your prescription changing their drug level.
Bottom Line Up Front
The 30-second version
- The axis changes from the other courses. Cardiac, renal, and hepatic disease bend the dose. A transplant bends the immunosuppressant interaction. The controlling question is not “how much do I reduce this?” but “what is my psychotropic doing to the tacrolimus level — and what is that doing to the graft?”
- The downside isn’t a side effect — it’s the organ. Push the calcineurin-inhibitor level down and you invite acute rejection; push it up and you invite nephrotoxicity and neurotoxicity. Both start with a psychotropic that touches CYP3A4.
- Two directions tell you the danger. Enzyme inducers (carbamazepine, St John’s wort) drive calcineurin-inhibitor levels down → rejection. Enzyme inhibitors (nefazodone, fluvoxamine) drive them up → toxicity. Nearly everything else is a relatively clean lane. Name the direction and you have the risk.
- Adherence is a prescribing variable here. Non-adherence carries roughly a seven-fold increase in graft-failure odds and is a leading cause of late graft loss. Treating the depression, the delirium, the substance use is not adjunctive — it is a graft-survival intervention.
Which Axis to Trust (60-Second Version)
The three prior courses trained one reflex: find the number, reduce the dose. A transplant inverts even the direction of the interaction. Immunosuppressants rarely force you to lower a psychotropic for clearance reasons — instead, the psychotropic you choose can change the immunosuppressant’s blood level, and the immunosuppressant is the one drug you cannot afford to move. So the point-of-care move isn’t to grade the transplanted organ; it’s to protect a trough.
This is the inversion worth internalizing. In most of medicine, the comorbidity acts on your drug. In transplant, your drug acts on the comorbidity’s treatment. Calcineurin inhibitors — tacrolimus and cyclosporine — are CYP3A4 and P-glycoprotein substrates with a narrow therapeutic index; a psychotropic that induces or inhibits CYP3A4 moves their level, and a small move crosses a big line.
Two axes run in parallel, and you have to hold both. The pharmacokinetic axis asks what your psychotropic does to the calcineurin-inhibitor concentration: an inducer strips it (rejection), an inhibitor stacks it (toxicity). The pharmacodynamic axis asks what the two do together regardless of level — additive QTc (tacrolimus itself prolongs the QT), additive nephrotoxicity (lithium on a calcineurin inhibitor), additive CNS depression, and a lowered seizure threshold in a patient whose immunosuppressant already flirts with neurotoxicity. A reassuring trough doesn’t clear the additive problem.
Why not just “reduce the dose”?
Because in transplant the drug you most need to keep steady isn’t yours — it’s the tacrolimus. Reducing your antidepressant does nothing to protect the graft if the antidepressant you chose is a CYP3A4 inducer quietly stripping the immunosuppressant. The safe move isn’t a smaller dose; it’s a drug that leaves the trough alone.
Rule Out the Drug and the Delirium First (the Gate No Other Course Has)
Before any of the pharmacology matters, the highest-yield move in transplant psychiatry is to confirm you are treating a psychiatric illness and not the immunosuppression itself. The regimen that keeps the graft alive is also a catalogue of neuropsychiatric adverse effects — and post-transplant delirium is common. As a rule, new psychiatric symptoms in a transplant recipient are drug-induced or medical until proven otherwise.
| Suspect first | What drives it | How it can look on a psych consult |
|---|---|---|
| Corticosteroids | Dose-related; risk rises steeply above ~40 mg/day prednisone-equivalent (psychiatric effects ~1.3% at ≤40 mg vs ~18% at ≥80 mg) | Mania, agitation, insomnia, depression, or frank psychosis — often in the first weeks, sometimes within days of a pulse. |
| Tacrolimus / cyclosporine (CNIs) | Tremor, insomnia, headache, anxiety even at therapeutic levels; supratherapeutic troughs raise the stakes | Restlessness and insomnia read as anxiety; at the severe end, PRES (posterior reversible encephalopathy) — confusion, seizures, visual change, high blood pressure — and rare psychosis. |
| The post-op / ICU course | Metabolic derangement, infection, polypharmacy, sedation in the early window | Delirium — fluctuating confusion and inattention mistaken for a new primary psychiatric illness. |
| mTOR inhibitors (sirolimus, everolimus) | Less CNS-active than the CNIs, but reported | Mood and anxiety symptoms; insomnia. |
The practical posture: in a transplant recipient with new neuropsychiatric symptoms, check the immunosuppressant list, the most recent calcineurin-inhibitor trough, and the steroid dose before you attribute the picture to a primary psychiatric disorder. Treat a steroid-driven mania by addressing the steroid with the transplant team — not by layering on a prescription that also collides with the calcineurin inhibitor.
The Two-Direction Model That Drives the Decision
Child-Pugh gave the hepatic course a single tool; eGFR gave the renal course one. In transplant, the anchoring tool is the direction your psychotropic pushes the calcineurin inhibitor. Every psychotropic a transplant prescriber worries about falls into one of three lanes, and the lane tells you what happens to the graft.
| Lane | Agents | Effect on the graft |
|---|---|---|
| CYP3A4 inducers CNI DOWN → rejection | Carbamazepine, oxcarbazepine, St John’s wort (and the barbiturates) | Strip the calcineurin inhibitor toward subtherapeutic troughs — the level falls over one to two weeks and rejection risk climbs silently. Carbamazepine is the sharpest: a named strong inducer that significantly lowers tacrolimus. |
| CYP3A4 inhibitors CNI UP → toxicity | Nefazodone (the FDA-label-named strong inhibitor); fluvoxamine (moderate CYP3A4, and a potent CYP1A2 inhibitor) | Raise calcineurin-inhibitor levels toward nephrotoxicity, tremor, and neurotoxicity. Here the victim is the graft’s own drug, not your psychotropic. |
| Relatively clean no meaningful CNI effect | Sertraline, escitalopram, most SSRIs, mirtazapine, bupropion; lamotrigine and valproate among mood stabilizers | The safe lanes — choose here first. Then still screen the additive axis (QT, nephrotoxicity, seizure threshold): “clean” is not “ignore.” |
One point on the victims: tacrolimus and cyclosporine — and the mTOR inhibitors sirolimus and everolimus — are the CYP3A4 substrates that swing. Mycophenolate and the steroids don’t ride CYP3A4 the same way, so the interaction lands mainly on the calcineurin and mTOR drugs. The single most useful habit: screen your psychotropic as a perpetrator before you screen it for side effects. Ask first — does this drug induce or inhibit CYP3A4? If yes, it will move the trough, and the transplant team needs to know before the first dose. If no, you are probably in a clean lane, and your attention shifts to the additive axis.
The Core Principle: There Is No Child-Pugh for the Graft
This is the idea to carry out of the chapter. The kidney hands you a filtration estimate; the liver hands you a class. The transplanted organ hands you neither number that governs psychopharmacology — because the thing you are dosing against isn’t the organ’s function, it’s the immunosuppressant trough. The tacrolimus level is the number you protect, and your job is to choose a psychotropic that doesn’t move it.
So the point-of-care question is not “How well is the graft working?” — it’s “What exact immunosuppressants is this patient on, and does my drug touch the enzyme that clears them?” Three things complicate the clean picture:
- The window is razor-thin. Calcineurin inhibitors have a narrow therapeutic index and high pharmacokinetic variability — the gap between a subtherapeutic trough (rejection) and a toxic one (nephrotoxicity) is small, so even a modest enzyme effect can push a patient across a clinically meaningful line.
- Induction lags, and so does the danger. Starting or stopping an inducer like carbamazepine takes one to two weeks to reach a new enzyme steady state — the trough drifts down (or back up) silently over days, not at the first dose. A drug you started last week can drive a rejection episode this week.
- The regimen is a moving target. Immunosuppression is tapered across the first post-transplant year — steroids come down, calcineurin-inhibitor targets are minimized — and early on a transplanted kidney is still recovering its clearance. Every immunosuppression change is a reason to re-check, and to re-run the interaction.
The Interaction Logic
Renal dosing had a clean gate; transplant has a short sequence of questions that size the interaction. Three frame the pharmacokinetic side:
| Question | What you’re asking | Why it matters |
|---|---|---|
| 1. Is my psychotropic a CYP3A4 perpetrator? | Does the drug I want induce or inhibit CYP3A4 / P-gp? | Sets the direction before you look at anything else. Inducer → trough down → rejection; inhibitor → trough up → toxicity; neither → probably clean. |
| 2. Which immunosuppressant is the victim? | Is the patient on a calcineurin or mTOR inhibitor (CYP3A4 substrates that swing) — or only mycophenolate and steroids? | A perpetrator only matters if the immunosuppressant rides the pathway it touches. Tacrolimus, cyclosporine, sirolimus, everolimus swing; the antimetabolite largely doesn’t. |
| 3. Which direction, and how much room is left? | How close is the current trough to target, and which way will my drug move it? | The narrow window means even a moderate shift can matter. Coordinate the anticipated change with the transplant team before, not after. |
The fourth question sits outside the pharmacokinetic logic
- What do the two add up to, regardless of level? That’s not an interaction you dose around — it’s an additive-risk decision. Additive QTc (tacrolimus prolongs the QT; stack a higher-risk antipsychotic and the risk compounds), additive nephrotoxicity (lithium on top of a calcineurin inhibitor — two nephrotoxins on one kidney), additive CNS depression, and a lowered seizure threshold in a patient whose calcineurin inhibitor can already provoke neurotoxicity. The trough can look perfect while the additive stack is what harms the patient. Treat it as a separate decision on the same patient.
Which Psychotropics Need Caution (Orientation)
This chapter gives you the map, not the agent-by-agent interaction tables — those live in the member chapters. The transplant landscape sorts by effect on the immunosuppressant rather than by clearance.
| Tier | Agents (orientation only) |
|---|---|
| Highest concern graft-threatening or additive-injury |
Carbamazepine and oxcarbazepine — strip the calcineurin inhibitor toward rejection (carbamazepine is functionally off the table as a first-line mood stabilizer here). St John’s wort — a classic cause of transplant rejection through induction. Nefazodone — the FDA-label-named strong CYP3A4 inhibitor — and fluvoxamine (a moderate CYP3A4 inhibitor, and a potent CYP1A2 inhibitor) drive calcineurin-inhibitor levels toward toxicity. Lithium with a calcineurin inhibitor — additive nephrotoxicity on a single kidney. |
| Adjust / watch level shifts or additive QT |
Higher-QT antipsychotics on tacrolimus (additive QTc; pimozide the standout to avoid), modafinil (weak-to-moderate CYP3A induction — the FDA label warns of reduced cyclosporine), and any CYP3A4-cleared agent whose own level rises on a strong inhibitor. Fluoxetine doesn’t meaningfully inhibit CYP3A4, so it won’t raise the trough — but it is a potent CYP2D6 inhibitor and adds to QTc, so watch those rather than the calcineurin level. |
| Relatively clean little effect on the trough |
Sertraline and escitalopram lead the antidepressant safe lane; mirtazapine and bupropion don’t meaningfully move the trough (bupropion still lowers the seizure threshold). Among mood stabilizers, lamotrigine and valproate replace carbamazepine. “Clean” is not “ignore”: the additive pharmacodynamic axis still applies. |
Two moves carry most of the benefit: screen the psychotropic as a CYP3A4 perpetrator before you choose it, and when you need a mood stabilizer reach for lamotrigine or valproate rather than the carbamazepine that would quietly threaten the graft.
The Organ and the Phase Change the Picture
One more layer the framework has to hold: which organ, and which phase. The immunosuppressant interaction is broadly the same across organs — nearly everyone is on a calcineurin inhibitor — but the surrounding constraints differ. A kidney recipient’s clearance is still recovering early on, which matters for renally-eliminated agents (lithium, gabapentin, pregabalin) and sharpens the additive nephrotoxicity of lithium on the calcineurin inhibitor. A liver recipient carries residual hepatic considerations and, frequently, an alcohol-use history that shapes both candidacy and relapse-prevention prescribing. Heart and lung recipients bring their own cardiac and functional constraints to the additive-QT and sedation questions.
Phase matters as much as organ. The early post-operative window is the delirium-and-high-steroid era: unstable levels, ICU physiology, pulse-dose steroids, and a high pretest probability that new symptoms are drug-induced or medical. The stable maintenance phase shifts the dominant risk to adherence and the chronic psychiatric illness that erodes it. Read the actual regimen and the phase every time — and when the regimen changes (a steroid taper, a calcineurin-inhibitor switch, a new inducer), re-run the interaction, because the trough can move a week or two later without anyone touching the psychiatric prescription.
The Action Ladder
Stable maintenance on a calcineurin inhibitor, graft functioning
Choose the psychotropic from the safe lanes (sertraline, escitalopram) on its own merits. Avoid carbamazepine and St John’s wort (they strip the calcineurin inhibitor); avoid fluvoxamine and nefazodone (they drive it toxic). Screen the additive axis — QT, nephrotoxicity, seizure threshold.
You need a mood stabilizer
Reach for lamotrigine or valproate, not carbamazepine or oxcarbazepine. If lithium is the right drug, coordinate closely: it stacks nephrotoxicity on the calcineurin inhibitor and an early graft’s clearance is still shifting — monitor levels and renal function with the transplant team.
A strong CYP3A4 perpetrator is unavoidable
If an inducer or inhibitor can’t be avoided, it’s a transplant-team event, not a solo psychiatric decision. The calcineurin-inhibitor dose and trough monitoring have to move in step, and the effect is silent for one to two weeks — flag it before the first dose.
New neuropsychiatric symptoms in a transplant recipient
Stop and rule out the drug and the delirium first — steroid effect, calcineurin-inhibitor neurotoxicity or PRES, and post-op or medical delirium — before you attribute the picture to primary psychiatric illness and prescribe into a calcineurin interaction.
Clinical Pearls
Pearls
- Protect the trough, not the organ. The number that governs transplant psychopharmacology is the calcineurin-inhibitor level — choose a drug that leaves it alone.
- Your prescription can cost the graft. Inducers (carbamazepine, St John’s wort) lower the calcineurin inhibitor toward rejection — the consequence is measured in graft loss, not side effects.
- Two axes, not one. A reassuring trough doesn’t clear an additive-QT or additive-nephrotoxicity problem — screen the pharmacodynamic stack separately.
- Induction is silent and delayed. A CYP3A4 inducer started this week drifts the trough down over one to two weeks — re-check after any change, and warn the transplant team before you start.
- Carbamazepine is off the table as a first-line mood stabilizer here. Lamotrigine and valproate do the job without stripping the immunosuppressant.
- New mania or psychosis is the drug until proven otherwise. Steroids above ~40 mg prednisone-equivalent and calcineurin-inhibitor neurotoxicity / PRES top the differential before a primary diagnosis.
- Lithium is two nephrotoxins on one kidney. On a calcineurin inhibitor — and especially in a recovering renal graft — watch levels and renal function closely.
- Adherence is the graft’s lifeline. Non-adherence roughly septuples graft-failure odds — treating depression and substance use is graft-survival work, not an add-on.
Red Flags — Stop and Reassess
Hold and look closer
- New psychosis, mania, confusion, seizure, or visual change in a transplant recipient — consider steroid effect, calcineurin-inhibitor neurotoxicity / PRES, and delirium before a primary psychiatric diagnosis.
- Carbamazepine or oxcarbazepine started, or already running, in a patient on tacrolimus or cyclosporine — a graft-threatening inducer; verify with the transplant team before continuing.
- St John’s wort or any new herbal or supplement in a transplant recipient — can lower immunosuppressant levels enough to cause rejection; stop and coordinate.
- Nefazodone (strong) or fluvoxamine (moderate) chosen for a patient on a calcineurin inhibitor — CYP3A4 inhibition drives the trough toward toxicity; pick a cleaner agent.
- A rejection episode or a jump in calcineurin-inhibitor level coinciding with a recent psychotropic start or stop — suspect an induction or inhibition effect on the trough and involve the transplant team urgently.
Patient Counseling Script
Plain-language script
“Your transplant medication and this psychiatric medication can affect each other — and the transplant drug is the one we have to keep exactly steady, because its level is what protects your new organ. That’s why I’m choosing this particular medication, one that shouldn’t change your transplant levels. A few things to know. First, never stop, start, or change any medication — including anything another doctor gives you — without telling us, because a change on one side can quietly move the other over a week or two. Second, please don’t add any herbal product or supplement, St John’s wort especially, without checking with us — some can weaken your transplant medicine and put your organ at risk. Third, taking your medications exactly as prescribed is the single most important thing you can do for your transplant; if cost, side effects, or remembering ever get in the way, tell us and we’ll fix it together. We work as one team with your transplant doctors on all of this.”
EMR / Documentation Template
References
- Prograf (tacrolimus) Prescribing Information. Astellas Pharma. (CYP3A4/CYP3A5 and P-glycoprotein substrate; narrow therapeutic index; CYP3A inducers lower and inhibitors raise tacrolimus concentrations; neurotoxicity including tremor and PRES.)
- Tacrolimus. StatPearls. NCBI Bookshelf; 2026. (Strong CYP3A inducers — rifampin, carbamazepine, phenytoin, phenobarbital, St John’s wort — significantly lower tacrolimus concentrations and increase the likelihood of rejection.)
- Birdwell KA, Decker B, Barbarino JM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. Clin Pharmacol Ther. (Narrow therapeutic index and large between-patient pharmacokinetic variability of tacrolimus.)
- Gümüš A, et al. Effect of tacrolimus formulation on its susceptibility to drug-drug interactions with St. John’s wort. Clin Pharmacol Drug Dev. 2024. (St John’s wort induction of CYP3A / P-gp lowers tacrolimus exposure.)
- Gorevski E, Succop P, Sachdeva J, et al. Is there an association between immunosuppressant medication adherence and depression, quality of life, and personality traits in the kidney and liver transplant population? Patient Prefer Adherence. 2013;7:301–307. (Non-adherence contributes substantially to graft loss; markedly increased graft-failure odds in nonadherent recipients.)
- Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc. 2006;81(10):1361–1367. (Dose is the primary risk factor; Boston Collaborative incidence 1.3% at ≤40 mg/d, 4.6% at 41–80 mg/d, 18.4% at ≥80 mg/d prednisone-equivalent.)
Last reviewed July 2026. Part of the Psychiatry Education Forum Academy; for clinician education — it supports, and does not replace, individual clinical judgment and current local protocols.
You have the framework. Now get the drug-by-drug answers.
This chapter taught you how to decide which way your psychotropic bends the immunosuppressant — and how to keep the trough question separate from the additive-risk question. The chapters ahead give you the agent-by-agent calls, starting with the immunosuppressants themselves and the antidepressant lane you’ll reach for most.
Educational use only. Refer to the sources cited above and current prescribing information for clinical decisions. Psychiatry Education Forum and authors assume no liability for use of this material.
Responses